Patients were enrolled in two separate cohorts that accrued sequentially : in cohort @ , patients were enrolled on the basis of their oestrogen receptor-positive and HER@-negative biomarker status alone , whereas in cohort @ they were also required to have cancers with amplification of cyclin D@ ( CCND@ ) , loss of p@ ( INK@A or CDKN@A ) , or both .